Structural Biology of Glycoproteins by Nettleship, Joanne E.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 3 
 
 
 
 
© 2012 Nettleship, licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Structural Biology of Glycoproteins 
Joanne E. Nettleship 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/48154 
1. Introduction 
In recent years, the field of structural biology has seen many advances in technology for the 
production of recombinant proteins, mainly led by the high-throughput techniques of the 
structural genomics community. These technologies have largely focussed on expression 
using Escherichia coli with around 88 % of the protein chains in the Protein Data Bank (PDB) 
in 2010 being produced using this bacterium [1]. However, many proteins require post-
translational modification for correct folding and/or activity. By far the most common 
modification is glycosylation and it has been estimated that over half of all human proteins 
including many membrane proteins are glycosylated [2-3]. Therefore, the production of 
correctly glycosylated proteins for functional and structural studies requires the use of 
eukaryotic systems [4].  
Glycoproteins represent a unique challenge to the structural biologist due to the size and 
heterogeneity of the oligosaccharide chains. Glycans can constitute from 1 % to over 80 % of 
the total protein mass [5] with variation in the type and number of sugars attached to a 
glycosylation site and also the occupancy of a site. The heterogeneity introduced by 
glycosylation can hinder crystallization of a glycoprotein [4] thus limiting the use of X-ray 
crystallography, one of the major techniques using in protein structure solution.  
The following chapter reviews options for the production of glycoproteins from different types 
of expression system, both prokaryotic and eukaryotic, along with methods for addressing 
glycan heterogeneity in order to produce homogeneous glycoprotein samples which are 
amenable for structural studies. The use of such homogeneous glycoprotein samples in both 
crystallization and nuclear magnetic resonance (NMR) experiments are discussed. 
2. Glycosylation in mammalian cells 
In eukaryotes, glycans are added to the polypeptide chain in the endoplamic reticulum  
(ER) and the Golgi as the protein is secreted (see Figure 1). There are two types of 
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glycosylation, one involves linkage of an oligosaccahride to an asparagine residue and the 
second involves linkage to a serine or threonine residue referred to as N- and O-
glycosylation respectively. 
 
 
Figure 1. Simplified representation of the N-glycosylation pathway in humans with the initial core 
Man9GlcNAc2 sugar being formed in the endoplasmic reticulum (ER) and further modifications taking 
place in the Golgi. 
N-glycosylation occurs co-translationally in the ER at the consensus sequon Asn-X-
Ser/Thr/Cys-X where X is any amino acid except proline. The exact sequence of the sequon 
has a bearing on the occupancy of the glycosylation site. N-glycosylation is often essential 
for the expression and folding of a glycoprotein [6], with the initial glycan formed in the ER 
being further modified and decorated in the Golgi apparatus. This elaboration of the glycan 
core leads to a large number of possible structures which are classified as high mannose, 
complex or hybrid (Figure 2). 
O-glycosylation (See Figure 3) usually occurs in regions containing large numbers of 
sequential serine, threonine and proline residues which are known as mucin domains. These 
regions show little secondary structure and are therefore often excluded from structural 
studies as proteins containing such disorder are unlikely to crystallize. O-glycosylation 
occurring outside mucin regions is difficult to predict accurately and so is usually only 
detected after production of a protein. As O-glycosylation occurs in the Golgi, it has little 
bearing on the early stages of protein folding and therefore sites found to be O-glycosylated 
can be engineered out of the protein by site-directed mutagenesis of the acceptor Ser/Thr 
residues. 
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Figure 2. Diagrammatic representation of the major classes of N-linked sugars produced by 
mammalian cells. 
 
Figure 3. Representation of the core structures of the common O-glycans produced by mammalian cells. 
3. Expression systems 
For the correct production and folding of glycoproteins, the expression host needs to post-
translationally modify the protein chain by adding sugars at the glycosylation sites. Therefore, 
production of glycoproteins is most often performed using eukaryotic cells, although the 
aglycosylated protein can be expressed as inclusion bodies in E. coli and refolded and also 
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produced using cell-free systems. Recent advances in glycosylation pathway engineering have 
resulted in both E. coli [7] and cell-free systems [8] which are capable of introducing N-
glycosylation onto a protein. These methods are discussed in the relevant sections below. 
In addition to finding an appropriate system for the over-expression of the target 
glycoprotein, the ability of this system to incorporate selenomethioine into the protein must 
be assessed. Selenomethioine labelling enables phasing of X-ray diffraction data by multi-
wavelength anomalous diffraction (MAD) [9]. Proteins expressed using E. coli routinely 
incorporate 100 % selenomethionine, whereas incorporation is more variable for proteins 
produced in higher eukaryotic systems. 
3.1. Escherichia coli 
E. coli is an attractive host as it is fast, simple to use, robust and cost-effective and therefore 
remains the dominant host for the production of recombinant proteins. In terms of 
glycoprotein production, the protein is usually expressed in inclusion bodies as bacteria do 
not have either the endoplasmic reticulum or the Golgi apparatus needed to secrete and 
post-translationally modify glycoproteins. As the protein is produced in inclusion bodies, 
refolding is needed to produce samples for structural biology – a process which can be time 
consuming and inefficient. However this method has proved useful for a number of 
products, for instance Watson et al. used E. coli to produce crystals of the extracellular 
domain of human UL16-binding protein ULBP1 [10]. Here the authors investigated various 
refolding strategies before finding the optimum protocol of slow dilution of guanidine-
solubilised protein in solution containing arginine, ethylenediaminetetraacetic acid, reduced 
and oxidized glutathione and phenylmethyl-sulphonyl fluoride over 48 hours. In addition, 
recently the crystal structures of the murine class I major histocompatibility complex H-2Kb 
(PDB entry 3ROL) [11] and human β-secretase I with bound inhibitors (PDB entry 3S7M and 
3S7L) [12] and the NMR structure of the sterile alpha motifs of EphA2 and SHIP2 (PDB 
entry 2KSO) [13] have solved using production in E. coli followed by refolding. 
Another approach is to express the glycoprotein in the periplasm of E. coli using a bacterial 
signal sequence such as OmpA. For example, human α1-microglubulin was produced in the 
periplasm of E. coli and used to obtain the crystal structure to 2.3 Å resolution which 
revealed a potential heme binding site (PDB entry 3QKG) [14]. 
Recently an engineered eukaryotic protein glycosylation pathway has been inserted into E. 
coli resulting in cells capable of producing glycoproteins with Man3GlcNAc2 sugars attached 
[7]. Four glycosyltransfereases from Saccharomyces cerevisae, the uridine diphosphate-N-
acetylglucosamine transferases Alg13 and Alg14 and the mannosyltransferases Alg1 and Alg2, 
are used to generate the glycan. The glycan is then transferred onto an N-glycosylation site 
using the oligosaccharyltransferase PglB from Campylobacter jejuni. Valderrama-Rincon et al. 
tested production of three eukaryotic glycoproteins; the Fc domain of human IgG1, bovine 
RNaseA and the placental variant of human growth hormone, and detected expression of 
glycosylated proteins [7]. Although currently only ~1 % of the expressed proteins were found 
to be glycosylated, this technology represents a huge potential for the cost-effective production 
of glycoproteins with a defined glycosylation pattern. 
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3.2. Insect cells 
Glycoproteins produced by insect cells, such as Spodoptera frugiperda, Trichoplusia ni and 
Drosophila melanogaster, express products with glycans which are oligomannose and 
paucimannose in nature and mainly of the form α1-6 fucosylated Man3GlcNAc2 (Figure 4A) 
[15]. This compact, relatively homogeneous glycoform is compatible with protein 
crystallization and a number of structures have been determined of glycoproteins produced 
using insect cells. For example, the crystal structure of FcγRIIa was solved to 1.5 Å 
resolution using baculovirus infected S. frugiperda (Sf) 21 cells (PDB entry 3RY4) and also its 
structure bound to human IgG1-Fc was resolved to 3.8 Å (PDB entry 3RY6) [16].  
 
Figure 4. Representation of the N-glycans attached to proteins produced by (A) insect cells; (B) the 
yeast Saccharomyces cerevisiae (selected yeast oligosaccharide); (C) mutant CHO and HEK cell lines; and 
(D) mammalian cell lines in the presence of small molecule inhibitors. 
The glycoforms produced by insect cells can be trimmed by treatment with 
endoglycosidases, for example endoglycosidase (endo) H or endo F1 and endo D will 
remove oligomannose and paucimannose sugars respectively leaving one GlcNAc residue 
on N-glcyosylation sites. In addition, endo F2 can be used in combination with endo F3 to 
cleave oligomannose and biantennary complex sugars and core fucosylated bi and 
triantennary complex gycans. Using this de-glycosylation strategy Fan et al. reported the 
successful crystallization and structure determination of a complex of human follicle 
stimulating hormone with its receptor (PDB entry 1XWD). Here crystals of fully 
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glycosylated complex diffracted to 9 Å whereas 2.9 Å resolution was obtained after de-
glycosylation with endo F2 and endo F3 [17]. Also, the structure of HIV-1 envelope 
glycoprotein gp120 was solved to 2.2 Å using de-glycosylation with endo H and endo D 
(PDB entry 1G9N) [18]. Although less common, tunicamycin has been used during 
production to block all glycosylation in order to promote crystallization. For example, 
evasin-1 structure was solved to 1.63 Å in its non-glycosylated form and to 2.7 Å in its 
glycosylated form (PDB entries 3FPR and 3FPT respectively) [19]. 
Selenomethionine labelling in insect cell systems can be difficult due to the toxicity of 
selenomethionine and the long incubation times needed as late baculovirus promoters such as 
polyhedron or P10 are normally used [1]. The levels of incorporation for secreted 
glycoproteins is higher than for intracellular proteins as unlabelled protein is removed during 
the media exchange process [20]. For example, 85 % selenomethionine incorporation was 
achieved for envelope glycoprotein D from HSV1 [21] and 76 % for palmitoyl protein 
thioesterase 1 (PDB entry 1EI9 and 1EH5) [22]. In 2007, Cronin et al. addressed this problem of 
variability in levels of incorporation and developed a method which consistently gave 70-75 % 
selenomethionine incorporation with a yield of around 20 % of the unlabelled protein [23]. 
3.3. Yeast cells 
Yeast have been used for the production of human glycoproteins, with the most popular 
expression hosts being Saccharomyces cerevisiae and Pichia pastoris [24-25]. Recombinant 
proteins are secreted and post-translationally glycosylated to give glycoforms that are 
sensitive to endo H or endo F1 treatment and are therefore suitable for crystallization 
(Figure 4B). For example, de-glycosylation of protein produced in P. pastoris was used to 
prepare the G-protein coupled receptor (GPCR) human β2 adrenergic receptor for 
crystallization [26] and production of gastric intrinsic factor with cobalamin (vitamin B12) 
bound (IF-Cbl) in P. pastoris was followed by complex formation with the cubilin IF-Cbl-
binding-region and endo H treatment prior to crystallization of the complex to give a 3.3 Å 
resolution crystal structure (PDB entry 3KQ4) [27]. 
There are examples in the literature where retaining the N-glycans on the glycosylated protein 
produced in yeast is important, such as the of human and mouse glutaminyl cyclases (QC), 
enzymes linked with Alzheimer’s disease, (PDB entry 3SI0) [28]. The structure of human QC 
had already been solved using protein produced in E. coli (PDB entry 2AFO) [29]. However, 
the glycosylated structure was shown to be more stable and to contain a disulphide bond not 
present in the non-glycosylated structure. The reduced stability of the aglycosylated human 
QC was associated with ready loss of the catalytic zinc ion [28].  
Production of selenomethionine labelled proteins is possible in yeast with incorporation 
levels of around 50 % routinely reported for both P. pastoris and S. cerevisiae [20]. However 
higher selenomethionine incorporation has been reported. For instance, incorporation of ~98 
% selenomethionine was reported for production of the carboxy-terminal fragment of the 
RNA-dependent RNA polymerase from Neurospora crassa, QDE-1 using S. cerevisiae [30]. 
This labelled protein was used to generate crystals which diffracted to 3.2 Å and allowed 
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phasing of the native data giving a 2.3 Å resolution crystal structure (PDB entry 2J7N). More 
recently Malkowski et al. described generation of a selenomethionine-resistant strain of S. 
cerevisiae by blocking the S-adenosylmethionine synthesis pathway [31]. This strain was 
used to produce tryptophanyl-tRNA synthetase with >95 % selenomethionine incorporation 
which led to the determination of the structure of this yeast enzyme. [31]. Using the strain to 
produce and label heterologous proteins has so far not been reported. 
3.4. Mammalian cells 
Mammalian cells are a popular choice for the expression of glycoproteins, particularly for 
the production of human proteins. These cells have the correct machinery to fold and post-
translationally modify glycoproteins. The two main cell lines used are human embryonic 
kidney (HEK) 293 cells and Chinese hamster ovary (CHO) cells, both of which are readily 
transfected with polythyleneimine (PEI), calcium phosphate or commercial lipids giving 
expression in 60-80 % of the cells [32-33]. There are two main variants of HEK 293 cells, (i) 
293T which expresses the SV40 large-T antigen and (ii) 293E which expresses the Epstein-
Barr virus (EBV) nuclear antigen 1 (EBNA1). Plasmids containing the SV40 or EBV origins of 
replication are amplified within these variants, giving more copies of the plasmid per cell 
and therefore a higher levels of protein expression [34]. An alternative method of 
introducing genes into mammalian cells is to use viral-mediated transduction such as the 
BacMam system [35], which has been shown to give milligram quantities of protein for 
structural studies [36]. 
Mammalian cells can be grown in either attached or suspension culture and automation of 
the culturing processes is possible in both cases [37-38]. Structural studies have been 
performed on proteins produced both by transient transfection, formation of a stable cell 
line, and using stable pools. Transient transfection is attractive due to the short timeframe 
between transfection and purified protein. Glycoprotein yields for non-antibodies of up to 
40 mg/L have been obtained from attached HEK cells [39] and 36 mg/L from HEK cells in 
suspension [40], with yields of 27 mg/L from CHO cells in suspension [40]. 
Formation of a stable cell line producing a glycoprotein of interest often gives higher yields 
than utilizing transient transfection, however establishment of a stable cell line can take 2-6 
months [41]. Automation can give a three-fold increase in throughput, although the timeline 
is the same [42]. An advantage of the system is that once the stable cell line has been 
established, production of the glycoprotein is fast and robust. 
Use of stable transfection pools for expression are becoming increasingly popular as the 
protein yield is usually higher than for transient transfection but the timeline is shorter than 
for making a stable cell line. Post-transfection, the cells are sorted, often using a fluorescence 
marker, in order to enrich the pool for high producers. Using such a method, highly 
productive pools of cells can be obtained in 3 weeks, though yields may decline over time in 
culture as the transfection cells are not clonal. Using this method, expression levels of 
monoclonal antibodies from 100 mg/L to 1 g/L can be achieved in 2 months post transfection 
using CHO cells [43]. 
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Selenomethionine labelling in mammalian cells is not as efficient as in E. coli, however levels of 
up to 90 % have been reported for stable HEK cell lines [44] and 78 % for transient 
glycoprotein production [1]. Generally cells are grown for a period of about 12 hours in media 
lacking methionine in order to deplete the intracellular methionine pools before the addition of 
selenomethionine. Keeping the concentration of selenomethionine used to 60 mg/L or below is 
important due to its toxicity which will lead to a lower yield of glycoprotein. 
Unlike insect and fungi, mammalian cells produce glycoproteins with complex 
oligosaccharide chains (Figure 2) which are very heterogeneous and therefore not readily 
amenable to crystallization. Complete removal of N-linked glycans can be achieved by 
treatment of a purified glycoprotein with Peptide N-glycosidase (PNGase) F thus aiding 
crystallization [45]. In practice, two problems are encountered which limit this approach. 
Firstly, incomplete removal of glycans leading to partial de-glycosylation of the product; 
and secondly, insolubility due to protein aggregation following removal of all the sugars. 
Alternatively, glycosylation can be completely blocked in cells by treatment with 
tunicamycin. However, if glycosylation is required for proper folding and/or solubility in 
situ, then this approach will compromise the synthesis of the product. Two methods have 
been developed to get round these problems both of which depend upon manipulating N-
glycosylation during glycoprotein biosynthesis by blocking the action of processing 
enzymes using either chemical inhibitors or null mutant cell lines. 
3.4.1. Inhibitors 
Three inhibitors have been used in the production of glycoproteins to manipulate the 
glycosylation pathway: N-butyldeoxynojirimycin (NB-DNJ), swainsonine and kifunensine. 
NB-DNJ inhibits α-glucosidase, thus blocking the early stages of N-glycan processing and 
giving products which contain high mannose or hybrid type sugars (Figure 4A). NB-DNJ 
has mainly being used in combination with the mutant CHO cell line, CHO Lec3.2.8.1 
(Section 3.4.2), for instance in the crystallization of human costimulatory molecule B7-1 
which is important in human immune response which gave crystals diffracting to 2.7 Å after 
treatment with endo H [46]. Swainsonine blocks α-mannosidase II resulting in high 
mannose or hybid type sugars shown in Figure 4D. Kifunensine strongly inhibits α-
mannosidase I activity resulting in sugars of the form Man9GlcNAc2 (Figure 4D) [4]. 
Treatment of cells with the any of the above inhibitors results in relatively simple and 
chemically uniform glycoforms. Further, the high mannose and hybrid glycans resulting 
from the use of these drugs are cleavable using endoglycosidase (endo) H or endo F1 to 
leave one GlcNAc residue attached to the N-glycosylation site.  
In practice, kifunensine is the most commonly used inhibitor in the production of 
glycoproteins for structural studies as the resulting glycans are the most homogeneous. In 
fact, the structures of glycoproteins can be solved following kifunensine treatment, without 
the use of endoglycosidase (for example, PDB entry 2WAH [47]), however more commonly 
the sugars are trimmed with endo H before crystallization studies. For example, Bishop et al. 
used transient transfection of HEK 293T cells in the presence of kifunensine to produce a 
number of glycoproteins involved in human Hedgehog signalling pathway. These were 
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treated with endo H before crystallization and co-crystallization to give structures of 
hedgehog interaction protein ectodomain (Hhip) and Desert hedgehog in isolation and Hhip 
in complex with Desert hedgehog and sonic hedgehog (PDB entries 2WFT, 2WFR, 2WFQ, 
2WG3, 2WFX and 2WG4) [48]. Production in the presence of kifunensine followed by endo 
H treatment has also been used with a stable CHO cell line in the crystallization of the 
extracellular region of cytotoxic T-lymphocyte antigen 4 (CTLA-4) giving crystals which 
diffracted to 1.8 Å [49].  
3.4.2. Mutant cell lines 
CHO and HEK cell lines have been generated with mutations in their glycosylation 
pathways which disrupt the action of GlcNAc transferase I (GnTI) [50-51]. CHO Lec3.2.1 
contains four mutations which are in the Gne, Slc35a1, Slc35a2 and Mgat1 open reading 
frames leading to lower activity of various glycosylation enzymes including GnTI [50]. Use 
of CHO Lec3.2.8.1 leads to proteins mainly containing high mannose glycans which are 
sensitive to removal of all but the last GlcNAc residue with endo H or endo F1 (Figure 4C). 
However, the mutations in CHO Lec3.2.8.1 do not completely inhibit the formation of 
complex glycans [50] with, in some cases, as little as 10 % of the glycoprotein produced 
being endoglycosidase sensitive [4]. Structural studies have been carried out using CHO 
Lec3.2.8.1 both in the absence and presence of NB-DNJ which has a complementary 
inhibition effect to the mutant cell line giving endoglycosidase sensitive sugars (For 
examples see [46, 52-54]). 
The GnTI-deficient cell line, HEK 293 GnTI- (also known as HEK 293S) produces glycoproteins 
with high mannose glycans (Figure 4C) which are endo H and endo F1 sensitive. Use of HEK 
293 GnTI- cells gives product containing a very uniform glycosylation pattern of the form 
Man5GlcNAc2 with only traces of other glycan patterns being detected [51, 55]. This cell line 
has proved popular, recently facilitating structure solution of NetrinG1 and NetrinG2 in 
complex with their respective ligands at 3.25 Å and 2.6 Å resolution respectively (PDB entries 
3ZYJ and 3ZYJ) [56]; the human glutamate receptor GluR2 amino terminal domain at 1.8 Å 
resolution (PDB entries 2WJW and 2WJX) [57]; and the orphan domain of the membrane 
glycoprotein endoglin using small angle X-ray scattering (SAXS) [58]. 
3.5. Other 
Although not currently in mainstream use for the production of glycoproteins, two other 
expression systems are worth mentioning, namely cell-based production in the protozoan 
Leishmania tarentolae and cell-free synthesis using coupled transcription-translation systems. 
The structure of human Cu/Zn superoxide dismutase has been recently published and 
represents the first structure solved using L. tarentolae as the expression host (PDB entry 
3KH3) [59]. The advantages of the L. tarentolae system (commercialized by Jena Biosciences 
as LEXSY) are that it is simple to use, gives high yields and is inexpensive compared with 
the higher eukaryotes. L. tarentolae has eukaryotic folding and post-translational machinery 
and has been used in a proof of principle experiment to express glycosylated human 
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erythropoietin [60]. These data show that use of L. tarentolae as a host system is applicable to 
the expression of glycoproteins for structural studies. 
Cell-free synthesis systems have been used for structural studies for a number of years and 
are commonly based on lysates from E. coli, wheat germ and rabbit reticulocytes [61]. 
Glycoproteins can be produced by supplementing lysates with microsomal fractions [62], or 
using extracts of eukaryotes such as insect cells [63], hybridomas [64] and mammalian cells 
[65], although the yields are often poor. These systems give glycosylation patterns native to 
the host which in the case of insect cells can be modified using endoglycosidases and in the 
case of mammalian cells can be blocked using inhibitors (Section 3.4.1). Recently both the E. 
coli lysate cell free synthesis system and the PURE system for in vitro translation using 
purified components of E. coli [66] have been adapted for production of glycoproteins [8]. In 
this article, Guarino and DeLisa used the protein glycosylation locus from Campylobater 
jejuni to supplement both systems and produce glycoprotein with the GlcGalNAc5Bac 
(where Bac represents bacillosamine) glycosylation pattern of C. jejuni (Figure 5) [8]. Cell-
free systems have yet to yield a glycosylated protein for which a structure has been 
deposited in the PDB. However the ability to micro-engineer the components of the 
glycosylation pathway in an “open system” is an interesting and useful addition to the 
structural biologist’s toolbox. 
 
Figure 5. Representation of the glycosylation pattern added to glycoproteins using the cell-free 
synthesis system of Guarino and DeLisa [8]. 
4. Variable occupancy of glycosylation sites 
In addition to the types of oligosaccharide chain attached to a glycosylation site, i.e. the 
glycoform, heterogeneity occurs in the occupancy of a glycosylation site. The occupancy of 
an N-glycosylation site depends upon the recognition sequon along with the structure of the 
protein in proximity to the glycosylation site. Some N-glycosylation sites have very low 
occupancy as a result of the local sequence composition, secondary structure and also 
distance to the C-terminus [67-69]. Bioinformatics programmes such as NetNGlyc and 
NetOGlyc (http://www.cbs.dtu.dk/services/NetNGlyc/ and http://www.cbs.dtu.dk/services 
/NetOGlyc/) [70-71] can predict occupancy of N-glycosylation and O-glycosylation sites 
respectively; however these are sequence based predictions and so need to be verified 
experimentally. After experimental identification of glycosylation site occupancy, variably 
occupied sites can be removed. Removal of variably occupied glycosylation sites should not 
affect the activity of a glycoprotein as these glycans are only present in a proportion of the 
sample and therefore must not be important for folding and solubility. 
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4.1. Identification methods 
Analysis of glycosylation site occupancy is usually carried out using mass spectrometry. For 
a review of recent developments in glycoprotein analysis and glycomics see Zaia [72]. In the 
most straightforward experiment, the occupancy of an N-glycosylation site can be 
determined using a combination of tryptic digest and PNGase F treatment, followed by 
analysis of the resulting peptide [73]. The peptide contains asparagine at the proposed site if 
no glycan is present and, due to the action of PNGase F, an aspartic acid if sugars are 
attached. As glycopeptides are not readily ionized within a mass spectrometer, they can be 
enriched in the sample using hydrophilic interaction liquid chromatography (HILIC), thus 
increasing the likelihood of a glycosylation site-containing peptide being detected [74-75]. 
Mapping of glycoproteins, including both analysis of the glycosylation site and analysis of 
the glycans themselves, has been miniaturized and automated, such as methods using 
functionalized magnetic nanoparticles [76] and integrating chromatography steps [77] 
which allow for rapid acquisition of results. 
Determination of O-glycosylation site occupancy is more difficult than for N-glycoslation 
sites as there is no endoglycosidase which universally releases O-linked glycans in the same 
way that PNGase F does for N-linked glycans. However, Halfinger et al. have developed a 
robust protocol using partial digestion with exoglycosidase and β-elimination using a mild 
alkylamine base followed by Michael addition and analysis using collision induced 
dissociation (CID) MS/MS [78]. 
Variable occupancy of glycosylation sites has also been detected by mutation studies. Here 
all the potential sites are mutated and the resulting protein analysed for activity. For 
example, Garman et al. analysed human IgE-FcεRIα and identified three glycosylation sites, 
N74, N135 and T142, which were not essential for protein folding, secretion and activity 
[79]. These sites were later confirmed by mass spectrometric analysis to be variably occupied 
[74]. However, mapping glycosylation occupancy by systematic mutation studies is labour 
intensive and is likely to result in many mutants that do not express or fold correctly as 
essential glycosylation sites have been removed. 
4.2. Removal of glycosylation sites 
Glycosylation sites found to be non-essential are often removed using site directed 
mutagenesis of the asparagine codon to a glutamine codon as this amino acid is similar in 
size and charge, but is not an attachment site for a glycan chain. 
Formation of an N174Q mutant version of human ephrinA2 was essential in obtaining 
crystals of the EphA4:ephrinA2 complex which resulted in the structure being solved to 2.3 
Å resolution (PDB entry 2WO3) [80]. In contrast, previous attempts at crystallization using 
wild type ephrinA2 with EphA4 were not successful. Although the N174 was shown to be 
invariably glycosylated, this site is not conserved across the ephrin family, (Nettleship, 
Bowden, unpublished results), and therefore was presumed to be non-essential. 
In the case of human alpha-N-acetylgalactosaminidase, which has five N-glycosylation sites, 
mutation of N201 to glutamine led to crystals giving diffraction to 1.9 Å resolution (PDB 
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entry 3H53) as opposed to the 8 Å resolution data collected using wild type glycoprotein 
crystals [81]. 
5. Structural studies 
5.1. Crystallization and X-ray crystallography 
Glycoproteins crystallize in a variety of conditions and trials are usually set up using the 
same screens as non-glycosylated proteins; such as those found in kits sold by Hampton 
Research, Molecular Dimensions and Emerald Biosystems. A number of reviews have 
addressed the problems connected with crystallization of glycoproteins such as the increase 
in surface entropy associated with large post-translational modifications and the 
microheterogenity of glycans [82-83]. However, it is to be noted that the presence of glycans 
can be an advantage for crystallization as they can form essential intermolecular contacts in 
crystal lattices [82]. Indeed glycoprotein crystallization has a success rate of around 50 % 
which is comparable to that for non-glycosylated proteins [82]. Methods around 
glycoprotein crystallization have developed to include automation and miniaturization 
using microscale crystallization techniques with as little as 65 μg of protein sample [45].  
The strategy which is unique to the crystallization of glycoproteins is manipulation of the 
glycoform as described above. Such manipulations affect the propensity of a glycosylated 
protein to crystallize and also the quality of the resulting crystals. As shown in Figure 6, the 
type of oligosaccharide attached to the protein affects crystal morphology. Interestingly, in 
the case of human IgE-FcεRIα, the Man5GlcNAc2 glycoform gave better diffracting crystals 
than the shorter Man1GlcNAc2 (Figure 6E and 6D respectively) and therefore setting up 
crystallization trials with more than one glycoform can be advantageous. 
X-ray crystal structures of glycoproteins often only show the initial GlcNAc residue even  
if more sugar residues are known to be attached to the protein because the glycan chains  
are flexible and so electron density for further sugar residues is not present. In rare cases, 
more of the oligosaccharide chain is resolved due to it either forming crystal contacts  
or interacting with the polypeptide chain. For example Figure 7 shows that the 
oligosaccharide chain attached to N297 of human IgG1-Fc could be fully resolved (PDB 
entry 2WAH) [47].  
In solving a glycoprotein structure, it is important that the carbohydrate chains are built 
into the relevant electron density taking into account the restrictions on sugar 
conformation, including torsion angles, and linkages found in nature [87-88]. Recently, 
Crispin et al. have described the biosynthesis of glycans with emphasis on how these 
pathways lead to the glycosidic linkages found in glycoprotein structures [88]. If the 
production host gave sugars of a defined composition, for example HEK 293 GnTI- gives 
sugars of the form Man5GlcNAc2, modelling the glycans is relatively straightforward. For 
other cases, there are a number of databases where the structures of known glycans are 
deposited, with GlycomeDB (www.glycome-db.org) being the most comprehensive and 
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unified carbohydrate database containing information from all public carbohydrate 
databases and the PDB [89-90]. Such databases are a useful resource for checking on the 
possible oligosaccharides and linkages likely to be attached to a glycoprotein produced 
using a given host cell. For building a three-dimensional model of an oligosaccharide 
chain, bioinformatics resources such as Sweet-II (www.glycosciences.de/spec/sweet2) [91] 
and Glycam Biomolecule Builder (glycam.ccrc.uga.edu/CCRC/biombuilder/biomb_ 
index.jsp) [92] are available. After modelling the glycan, Glycam Biomolecule Builder 
attaches the sugar chain to the protein structure at the glycosylation site, with glycans 
generated by Sweet-II being attached using the glyProt software (www.glycosciences.de/ 
modeling/glyprot/php/main.php) [93]. Upon deposition of the glycoprotein structure into 
the PDB, pdb-care (PDB carbohydrate residue check) can help with problems found 
within glycan structures [94-95]. Overall, use of these web-based tools allows for the 
correct building of sugar chains into glycoprotein structures when electron density is 
available. 
 
 
 
 
 
Figure 6. Crystals of human programmed cell death 1-ligand 1 formed from glycoprotein secreted by 
HEK 293T cells (A) in the presence of kifunensine and (B) after treatment with endo F1. Diffraction was 
to 7 Å and 3.7 Å respectively. Crystals of human IgE-FcεRIα (N74A, N135A, T142A) from protein 
produced using HEK 293T cells (C) in the presence of kifunensine; (D) after treatment with jack bean 
mannosidase and (E) produced by HEK 293 GnTI- cells. Diffraction was around 10 Å, to 6 Å and to 3.5 
Å respectively. In each case the insert shows the major glycosylation state of the protein upon 
crystallization and the resolution of diffraction data collected. (Human programmed cell death 1-ligand 
1 - PDB entry 3BIS [84] and human IgE-FcεRIα - PDB entry 2Y7Q [85]) 
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Figure 7. Cartoon representation of the human IgG1-Fc glycan attached to N297 shown as sticks in red 
with the protein backbone shown in green. The glycoprotein was produced in HEK 293T cells in the 
presence of kifunensine, giving sugars of the form Man9GlcNAc2. (The diagram was produced using 
PyMOL [86] and PDB entry 2WAH [47]). 
5.2. NMR spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy can be used to study protein structure, but 
the technique faces some obstacles in terms of its use for glycoproteins, namely the 1H 
chemical shift overlap between carbohydrate and protein signal [96] and the difficulty of 
obtaining sufficient yield of labelled protein from eukaryotic systems. These challenges have 
led to the majority of glycoproteins structures solved by NMR being of the aglycosylated 
protein chains expressed in E. coli.  
Labelling with 15N or both 15N and 13C has been demonstrated in mammalian cells [97], 
insect cells [98] and yeast [99]. Such eukaryotic expression systems have been used to solve a 
few recombinant glycoprotein structures containing glycans such as fragments of human 
fibronectin (PBD entry 1E8B), human thrombomadulin (PBD entry 1DQB) and the 
extracellular domain of human cytotoxic T lymphocylte-associated protein (CTLA)-4 (PDB 
entry 1AH1) [100-102]. 
The problem of signal overlap between proteins and carbohydrates has been tackled by 
Slynko et al. who added unlabelled glycan chains using in vitro N-glycosylation technology 
[103] to AcrA from C. jejuni produced using E. coli with 15N and 13C labelling (PDB entry 
2K32) [96]. This allowed a NOESY (Nuclear Overhauser effect spectroscopy) experiment to 
be performed without confusion between protein and glycan resonances which often cause 
difficulty in structure determination of unlabelled or 15N-labelled glycoproteins [96]. 
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In NMR structures, the protein chains and attached glycans are in solution and so are able to 
move around. Unlike in crystal structures, solution NMR allows the flexibility of both the 
oligosaccharide chain and the protein chain around a glycosylation site to be observed. In 
the case of AcrA (PDB entry 2K32), the flexibility was seen to be in the α-helical loop region 
containing the N42 glycosylation site (Figure 8A), with the heptasaccharide glycan having a 
well defined rod-like structure [96]. Human CTLA4 (PDB entry 1AH1) contains two N-
glycosylation sites, N78 and N111 which are occupied with partially deglycosylated glycans 
of the form Man1GlcNAc2 (Figure 8B). The glycan attached to N78 interacts extensively with 
the side chains of a nearby β-sheet and is therefore ordered, whereas N111 had limited 
interaction with the protein chain and so only the initial GlcNAc residue is well defined 
[102]. 
 
Figure 8. (A) Cartoon representation of the NMR ensemble structure of AcrA showing the N42 
glycosylation site (in red) in the flexible lower domain of the protein. (B) A space filling model of 
CTLA4 with the glycans attached to N78 (in red) showing interaction with the nearby β-sheet and the 
N111 sugar chain (in blue) being remote from the polypeptide chain. (Diagrams were produced using 
PyMOL [86] and PDB entries 2K32 [96] and 1AH1 [102] respectively). 
6. Conclusions and future prospects 
This chapter has reviewed some of the recent developments in the field of glycoprotein 
structural biology. Increasingly, the expression system of choice for the production of 
recombinant glycoproteins is the mammalian cell, and in particular HEK in the presence of 
kifunensine which modifies glycan processing. This enables treatment of the purified 
glycoprotein with endoglycosidase to reduce the sugar “load” to a single GlcNAc at each N-
linked attachment site. Experience shows that by preparing glycoproteins with different 
 
Glycosylation 56 
glycoforms the chances of obtaining diffraction quality crystals are significantly increased. 
Combining this approach with the inclusion of novel additives in the crystallization 
experiment, for example “smart materials”, such as the molecularly imprinted polymers 
(MIPs) recently reported by Sarkidakis et al. [104], adds another dimension to crystallization. 
Future developments in simpler low cost expression technology as exemplified by 
Leishmania tarentolae system will also have an impact on the structural biology of 
glycoproteins. It is anticipated that the number of structures solved by X-ray 
crystallography and NMR for this important class of proteins will rapidly increase in the 
next few years. 
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